H. Maeda

发表

Tandemly repeated Fc domain augments binding avidities of antibodies for Fcgamma receptors, resulting in enhanced antibody-dependent cellular cytotoxicity.

Y. Masuho, H. Nagashima, J. Kohroki, 2008, Molecular immunology.

ADAMTS-13 cysteine-rich/spacer domains are functionally essential for von Willebrand factor cleavage.

T. Miyata, K. Kokame, T. Nakagaki, 2003, Blood.

The authors state no conflict of interest.

M. Yamashita, H. Karasuyama, H. Maeda, 2012 .

Structural characterization and biological activities of an exopolysaccharide kefiran produced by Lactobacillus kefiranofaciens WT-2B(T).

Shiho Suzuki, H. Maeda, Kiyoshi Suzuki, 2004, Journal of agricultural and food chemistry.

A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease?

T. Hamamoto, T. Nakagaki, H. Maeda, 2001, Journal of biochemistry.

Identification of selenoprotein P fragments as a cell-death inhibitory factor.

Yoshiro Saito, Kazuhiko Takahashi, H. Maeda, 2003, Biological & pharmaceutical bulletin.

Production of human monoclonal and polyclonal antibodies in TransChromo animals.

H. Yoshida, I. Ishida, E. Halk, 2002, Cloning and stem cells.

Serum selenoprotein-P levels in patients with inflammatory bowel disease.

O. Inatomi, A. Andoh, Y. Fujiyama, 2005, Nutrition.

Inhibition of neutrophil migration in mice by mouse formyl peptide receptors 1 and 2 dual agonist: indication of cross‐desensitization in vivo

H. Maeda, K. Hirahara, Y. Sogawa, 2011, Immunology.

The pyrazolone originally reported to be a formyl peptide receptor (FPR) 2/ALX-selective agonist is instead an FPR1 and FPR2/ALX dual agonist.

H. Maeda, K. Hirahara, Y. Sogawa, 2009, Journal of pharmacological sciences.

Evaluation of the therapeutic index of a novel phosphodiesterase 4B-selective inhibitor over phosphodiesterase 4D in mice.

Satoshi Nakamura, T. Mikkaichi, H. Maeda, 2013, Journal of pharmacological sciences.

Production of a neutralizing mouse-human chimeric antibody against botulinum neurotoxin serotype E.

S. Kozaki, H. Maeda, C. Nozaki, 2013, Japanese journal of infectious diseases.

Characterization of neutralizing mouse‐human chimeric and shuffling antibodies against botulinum neurotoxin A

S. Kozaki, H. Maeda, C. Nozaki, 2012, Microbiology and immunology.

Effects of an exopolysaccharide (Kefiran) from Lactobacillus kefiranofaciens on blood glucose in KKAy mice and constipation in SD rats induced by a low-fiber diet

T. Mitsuoka, H. Maeda, Xia Zhu, 2004 .

New medium for the production of exopolysaccharide (OSKC) by Lactobacillus kefiranofaciens

T. Mitsuoka, H. Maeda, Xia Zhu, 2003 .

Production of transgenic chimera rabbit fetuses using somatic cell nuclear transfer.

T. Tokunaga, Seiya Takahashi, H. Maeda, 2002, Cloning and stem cells.

Formyl peptide receptor 1 and 2 dual agonist inhibits human neutrophil chemotaxis by the induction of chemoattractant receptor cross-desensitization.

H. Maeda, K. Hirahara, Y. Sogawa, 2011, Journal of pharmacological sciences.

Effects of an exopolysaccharide (kefiran) on lipids, blood pressure, blood glucose, and constipation

Shiho Suzuki, H. Maeda, S. Kitamura, 2004, BioFactors.

A newly derived protein from Bacillus subtilis natto with both antithrombotic and fibrinolytic effects.

M. Hitosugi, S. Tokudome, H. Maeda, 2005, Journal of pharmacological sciences.

Fibrinolytic and anti‐thrombotic effect of NKCP, the protein layer from Bacillus subtilis (natto)

M. Hitosugi, S. Tokudome, H. Maeda, 2004, Biofactors.

Melanocortin receptors 1 and 5 might mediate inhibitory effects of α-melanocyte-stimulating hormone on antigen-induced chronic allergic skin inflammation in IgE transgenic mice.

M. Yamashita, H. Karasuyama, H. Maeda, 2012, The Journal of investigative dermatology.

Potent cough suppression by physiologically active substance in human plasma.

Sachie K. Ogawa, N. Akaike, M. Wakita, 2014, General physiology and biophysics.